Search Within

Heather Jolie Landau

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (118)
  2. Journal Article (41)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Bone Marrow Transplant (162)
  2. Center for Hematologic Malignancies (162)
  3. Department of Medicine (162)
  4. Epidemiology and Biostatistics (162)
  5. Hematologic Malignancies, Division of (162)
  6. Survivorship Research (162)

More Groups

People
  1. Sergio Giralt (151)
  2. David Chung (135)
  3. Hani Hassoun (124)
  4. Alexander Lesokhin (121)
  5. Gunjan Shah (100)
  6. Neha Korde (94)

More People

Years
  1. 2025 (3)
  2. 2024 (15)
  3. 2023 (25)
  4. 2022 (24)
  5. 2021 (9)
  6. 2020 (12)

More Years

Publications
  1. Blood (68)
  2. Clinical Lymphoma, Myeloma and Leukemia (27)
  3. Biology of Blood and Marrow Transplantation (21)
  4. Journal of Clinical Oncology (7)
  5. Leukemia and Lymphoma (7)
  6. Blood Cancer Journal (5)

More Publications

Publishers
  1. American Society of Hematology (69)
  2. Elsevier Inc. (51)
  3. Nature Publishing Group (13)
  4. American Society of Clinical Oncology (7)
  5. Taylor & Francis Group (7)
  6. American Association for Cancer Research (3)

More Publishers

Results (162)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse
    Journal Article

    DeWolf, S.; Elhanati, Y.; Nichols, K.; Waters, N. R.; Nguyen, C. L.; Slingerland, J. B.; Rodriguez, N.; Lyudovyk, O.; Giardina, P. A.; Kousa, A. I.; more...
    Science Translational Medicine (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save